HALO
HALOZYME THERAPEUTICS, INC.
Latest Form 4:Sale$2.1MbyTorley Helen (PRESIDENT AND CEO) · filed Aug 19, 2026
HALOZYME THERAPEUTICS, INC. (HALO) has 43 SEC Form 4 filings (186 transaction rows) in the rolling window, disclosed by 5 distinct insiders. Most recent filing: Aug 19, 2026.
The most active filer is PRESIDENT AND CEO Torley Helen with 29 filings. Insiders have net sold $22.9M over the trailing 6 months.
- Industry:Biotechnology
- CEO:Helen I. Torley
- Employees:350
- HQ:San Diego, CA, US
- IPO:2004-03-16
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$43.6M
reported sales (SEC code S)
Unique Insiders
5
in the rolling window
Market Cap
$12.0B
latest known value
| Source | ||||||
|---|---|---|---|---|---|---|
| PRESIDENT AND CEO | Sale | 20,000 | $2.1M | Aug 19 | SEC ↗ | |
| PRESIDENT AND CEO | Sale | 20,000 | $2.1M | Aug 19 | SEC ↗ | |
| PRESIDENT AND CEO | Sale | 20,000 | $2.1M | Aug 19 | SEC ↗ | |
| Director | Sale | 1,626 | $167K | Aug 11 | SEC ↗ | |
| PRESIDENT AND CEO | Sale | 1,923 | $153K | Jul 9 | SEC ↗ | |
| Director | Sale | 1,625 | $125K | Jul 2 | SEC ↗ | |
Krishnan MaheshFirst filing | Director | Sale | 7,304 | $548K | Jun 30 | SEC ↗ |
| PRESIDENT AND CEO | Sale | 20,000 | $1.4M | Jun 3 | SEC ↗ | |
| PRESIDENT AND CEO | Sale | 20,000 | $1.3M | Jun 3 | SEC ↗ | |
| PRESIDENT AND CEO | Sale | 10,000 | $691K | Jun 3 | SEC ↗ | |
| Director | Sale | 1,625 | $108K | Jun 2 | SEC ↗ | |
| PRESIDENT AND CEO | Sale | 20,000 | $1.3M | May 13 | SEC ↗ | |
| PRESIDENT AND CEO | Sale | 20,000 | $1.4M | May 13 | SEC ↗ | |
| PRESIDENT AND CEO | Sale | 10,000 | $692K | May 13 | SEC ↗ | |
Connaughton BernadetteFirst in 4 months | Director | Sale | 1,625 | $103K | May 5 | SEC ↗ |
| PRESIDENT AND CEO | Sale | 10,000 | $635K | Apr 7 | SEC ↗ | |
| PRESIDENT AND CEO | Sale | 20,000 | $1.3M | Apr 2 | SEC ↗ | |
| PRESIDENT AND CEO | Sale | 20,000 | $1.3M | Apr 2 | SEC ↗ | |
| SVP, CHIEF OPERATING OFFICER | Sale | 20,000 | $1.4M | Mar 10 | SEC ↗ | |
| SVP, CHIEF OPERATING OFFICER | Sale | 8,857 | $599K | Mar 10 | SEC ↗ | |
| PRESIDENT AND CEO | Sale | 20,000 | $1.4M | Mar 4 | SEC ↗ | |
| PRESIDENT AND CEO | Sale | 20,000 | $1.4M | Mar 4 | SEC ↗ | |
| PRESIDENT AND CEO | Sale | 10,000 | $702K | Mar 4 | SEC ↗ | |
| PRESIDENT AND CEO | Sale | 20,000 | $1.5M | Feb 5 | SEC ↗ | |
| PRESIDENT AND CEO | Sale | 20,000 | $1.5M | Feb 5 | SEC ↗ | |
| PRESIDENT AND CEO | Sale | 10,000 | $786K | Feb 5 | SEC ↗ | |
| Director | Sale | 2,000 | $141K | Jan 6 | SEC ↗ | |
Caudill CortneyFirst filing | SVP, CHIEF OPERATING OFFICER | Sale | 4,263 | $278K | Dec 19 | SEC ↗ |
| PRESIDENT AND CEO | Sale | 16,569 | $1.1M | Dec 1 | SEC ↗ | |
| Director | Sale | 829 | $59K | Dec 1 | SEC ↗ | |
| PRESIDENT AND CEO | Sale | 20,000 | $1.4M | Nov 12 | SEC ↗ | |
| PRESIDENT AND CEO | Sale | 20,000 | $1.4M | Nov 12 | SEC ↗ | |
| PRESIDENT AND CEO | Sale | 20,000 | $1.4M | Nov 12 | SEC ↗ | |
| Director | Sale | 2,000 | $137K | Nov 12 | SEC ↗ | |
| PRESIDENT AND CEO | Sale | 20,000 | $1.5M | Oct 3 | SEC ↗ | |
| PRESIDENT AND CEO | Sale | 20,000 | $1.4M | Oct 3 | SEC ↗ | |
| PRESIDENT AND CEO | Sale | 20,000 | $1.4M | Oct 3 | SEC ↗ | |
| Director | Sale | 2,000 | $150K | Oct 1 | SEC ↗ | |
| SVP, CHIEF FINANCIAL OFFICER | Sale | 2,227 | $174K | Sep 23 | SEC ↗ | |
LaBrosse NicoleFirst filing | SVP, CHIEF FINANCIAL OFFICER | Sale | 20,000 | $1.5M | Sep 11 | SEC ↗ |
Torley HelenFirst filing | PRESIDENT AND CEO | Sale | 20,000 | $1.5M | Sep 4 | SEC ↗ |
Torley HelenFirst filing | PRESIDENT AND CEO | Sale | 20,000 | $1.5M | Sep 4 | SEC ↗ |
Torley HelenFirst filing | PRESIDENT AND CEO | Sale | 20,000 | $1.5M | Sep 4 | SEC ↗ |
Connaughton BernadetteFirst filing | Director | Sale | 4,000 | $295K | Sep 2 | SEC ↗ |
Related companies
HALOZYME THERAPEUTICS, INC. is in the Healthcare sector.